Slingshot members are tracking this corporate initiative:
AstraZeneca (AZN) strikes collaboration worth $6.9B to sell and develop Daiichi Sankyo's (DSNKY) HER2-targeting antibody-drug conjugate, Trastuzumab deruxtecan
Do you think this event is important to the companies below? How will it affect their stock price?
Shares in Daiichi surged 16% in Tokyo on news of the deal, which AstraZeneca will partly fund through a $3.5B share sale and $1.35B upfront payment.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Mar 29, 2019 Projected Implementation: Q1, 2019 Relevance Tracked Until: Q3, 2019
Don’t see a project related to the strategic initiative you care about?
Related Keywords Trastuzumab Deruxtecan, Her2